VOA常速英语2022 伊朗称逮捕三名与摩萨德有关的人（在线收听）

Iranian state television said intelligence officers arrested three people with ties to Israel's Mossad agency who were charged with involvement in releasing classified information.

伊朗国家电视台表示，情报官员逮捕了三名与以色列摩萨德情报局有关的人，他们被控参与泄露机密信息。

The report Thursday didn't identify them or how they had access to classified information.

周四的报道没有指明他们的身份，也没有说明他们是如何获得机密信息的。

Iran and Israel have long accused each other of spying and waging a shadow war for years.

多年来，伊朗和以色列一直指责对方从事间谍活动并发动影子战争。

Israel views Iran as its greatest threat and has repeatedly threatened to take military action against Iran to prevent it from acquiring nuclear weapons.

以色列将伊朗视为其最大威胁，并一再威胁要对伊朗采取军事行动，以阻止其获得核武器。

Iran denies it is seeking such weapons and has vowed a harsh response to any aggression.

伊朗否认正在寻求此类武器，并誓言会对任何侵略行为作出严厉回应。

Iran doesn't recognize Israel and supports anti-Israeli armed groups, such as Hezbollah and Hamas.

伊朗不承认以色列，并支持反以色列的武装组织，比如真主党和哈马斯。

The World Health Organization says it strongly recommends Pfizer's COVID-19 antiviral pill Paxlovid for patients with milder forms of the disease who are still at a high risk of hospitalization.

世界卫生组织表示，强烈推荐给病情较轻、仍有较高住院风险的患者使用辉瑞公司的抗新冠病毒药物Paxlovid。

But the U.N. agency warned it was, in its words, "extremely concerned" that the inequality in access seen with COVID-19 vaccines would again leave low- and middle-income countries at the end of the line waiting for those COVID pills.

但该联合国机构警告称，它“非常担心”新冠疫苗接种方面的不平等将再次出现，使中低收入国家排在最后，一直等待着获得这些新冠药物。

The WHO said in a BMJ medical journal that Pfizer's pill was the "superior choice" of treatment for the unvaccinated, elderly or immunocompromised people with COVID-19.

世界卫生组织在《英国医学杂志》上表示，辉瑞的药物是未接种疫苗的、年长的或免疫功能低下的新冠患者的“最佳治疗选择”。

For the same patients, the WHO made a "conditional recommendation," that's its term, of the antiviral drug remdesivir, made by the U.S. biotech firm Gilead, that it had previously recommended against.

对于同类型的患者，世界卫生组织“有条件地推荐”（其所用术语）美国生物技术公司吉利德生产的抗病毒药物remdesivir，此前世卫组织不建议使用该药物。

The WHO recommended Paxlovid over remdesivir, as well as over Merck's COVID-19 pill and monoclonal antibodies.

世卫组织更推荐使用Paxlovid，胜过remdesivir，也胜过默克公司的新冠药物和单克隆抗体。